Finding Promiscuous Old Drugs for New Uses
Finding Promiscuous Old Drugs for New Uses
复制标题
DOI：
10.1007/s11095-011-0486-6
复制
发表时间：
2011-08-01
影响因子：
3.7
通讯作者：
Williams, Antony J.
中科院分区：
文献类型：
--
作者：
Ekins, Sean;Williams, Antony J.
从过去六年发表的研究中，我们已经确定了34项研究，这些研究针对各种全细胞或靶向测定筛选了FDA批准的药物库。这些研究各自鉴定了一种或多种具有先前未描述的新生物活性的化合物。我们现在发现，这些药物中有13种对一种以上的疾病有活性，从而表明了一定程度的滥交。我们还表明，所有的研究编译后，109个分子被确定在体外筛选。这些分子似乎在统计学上更具疏水性，分子量和AlogP高于FDA指定的产品，这些产品至少有一个常见疾病适应症的上市批准或一个来自FDA罕见疾病研究数据库的罕见疾病的上市批准。获取这些关于旧药物用于新用途的体外数据对于其他人重新使用或重新定位这些或其他现有药物的潜在重复使用和分析将非常重要。我们已经建立了可供公众搜索的数据库，并设想随着更多研究的发表，这些数据库可以更新。
From research published in the last six years we have identified 34 studies that have screened libraries of FDA-approved drugs against various whole cell or target assays. These studies have each identified one or more compounds with a suggested new bioactivity that had not been described previously. We now show that 13 of these drugs were active against more than one additional disease, thereby suggesting a degree of promiscuity. We also show that following compilation of all the studies, 109 molecules were identified by screening in vitro. These molecules appear to be statistically more hydrophobic with a higher molecular weight and AlogP than orphan-designated products with at least one marketing approval for a common disease indication or one marketing approval for a rare disease from the FDA's rare disease research database. Capturing these in vitro data on old drugs for new uses will be important for potential reuse and analysis by others to repurpose or reposition these or other existing drugs. We have created databases which can be searched by the public and envisage that these can be updated as more studies are published.